NRx Pharmaceuticals Announces First Successful Commercial Formulation for ZYESAMI™ (aviptadil), Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication Subject to Regulatory Approval
– NRx has Validated a Formulation, Manufacture, and Container Closure Method Suitable for High Volume Manufacture with Anticipated 1 year or greater stability
– New Manufacturing Method Designed According to Good Manufacturing Practices (GMP) Regulations…
